ThromboGenics’ Jetrea Clears Advisory Panel, But Questions On Population Size Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 10-0 that the risk-benefit ratio of ocriplasmin for vitreomacular adhesions is positive, and 6-3 that no additional pre-approval studies are needed.